Should Tacrolimus Be Held in Acute Kidney Injury?
Do not routinely hold tacrolimus in acute kidney injury (AKI) following kidney transplantation; instead, measure tacrolimus trough levels immediately and reduce the dose or temporarily interrupt therapy only if levels are supratherapeutic (above target range), as the risk of acute rejection from complete withdrawal typically outweighs the reversible nephrotoxic effects of appropriately dosed tacrolimus. 1
Clinical Reasoning and Evidence-Based Approach
The KDIGO guidelines explicitly recommend measuring calcineurin inhibitor (CNI) blood levels whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection 1. This is the critical first step—check the tacrolimus level before making any dosing decision.
Decision Algorithm for AKI in Transplant Recipients on Tacrolimus:
Step 1: Measure tacrolimus trough level immediately
- If trough is above therapeutic range: Consider dose reduction or temporary interruption 1, 2
- If trough is within therapeutic range: Investigate alternative causes of AKI before adjusting tacrolimus
- If trough is below therapeutic range: Do not reduce dose; risk of rejection is paramount
Step 2: Evaluate for tacrolimus toxicity vs. other AKI causes
The FDA label clearly states that acute renal impairment associated with tacrolimus toxicity typically presents with high serum creatinine, hyperkalemia, and elevated tacrolimus trough concentrations, and is usually reversible 2. Recent research confirms that tacrolimus-induced AKI occurred in 47.3% of ulcerative colitis patients, particularly when trough values exceeded target levels 3, and that slow metabolizers (C/D ratio ≥420) had 3.72-fold higher risk of moderate-to-severe AKI 4.
Step 3: Consider biopsy if diagnosis unclear
KDIGO strongly recommends kidney allograft biopsy for all patients with declining kidney function of unclear cause to detect potentially reversible causes (1C evidence) 1. This distinguishes CNI toxicity from acute rejection—a critical distinction that determines whether to reduce or maintain immunosuppression.
Key Nuances and Pitfalls
The Rejection Risk Cannot Be Overstated
Complete withdrawal of tacrolimus creates immediate risk of acute cellular rejection, which can lead to graft loss—a catastrophic outcome affecting both mortality and quality of life. The 2025 EAU guidelines emphasize that tacrolimus is first-line therapy specifically because it provides superior rejection prophylaxis 5. KDIGO recommends that CNIs be continued rather than withdrawn in long-term maintenance (2B evidence) 1.
When Temporary Interruption Is Appropriate
The FDA label and case reports support temporary tacrolimus withdrawal specifically when:
- Trough levels are markedly elevated (>15-20 ng/mL or higher) 2, 6, 7
- Clear evidence of tacrolimus toxicity exists (neurotoxicity, very high creatinine with supratherapeutic levels)
- Drug-drug interactions cause severe toxicity (e.g., ritonavir interaction leading to levels of 118 µg/L) 6
In these cases, withhold for days, not weeks, with recommencement guided by frequent therapeutic drug monitoring 6, 7.
Dose Reduction vs. Complete Holding
For patients with chronic allograft injury (CAI) and histological evidence of CNI toxicity, KDIGO suggests reducing, withdrawing, or replacing the CNI (2C evidence) 1—note that reduction is listed first. Complete withdrawal is reserved for specific scenarios with alternative immunosuppression available.
Monitoring Strategy During AKI
- Measure tacrolimus levels every other day until stable 1
- Monitor serum creatinine daily 1
- Check for hyperkalemia (common with tacrolimus) 2
- Assess for concomitant nephrotoxic drugs (aminoglycosides, NSAIDs, other nephrotoxins) 2
Special Considerations
Drug interactions: When AKI occurs with concurrent CYP3A4 inhibitors (azoles, calcium channel blockers, ritonavir), tacrolimus levels can be dangerously elevated even at usual doses 2, 6. These require dose reduction or temporary interruption with close monitoring.
Hepatic dysfunction: Post-transplant hepatic impairment increases tacrolimus levels and AKI risk; lower doses are warranted 2.
The "drainage" context: If the question refers to urological drainage procedures (nephrostomy, ureteral stents) for obstruction, these are mechanical issues unrelated to tacrolimus toxicity. Continue tacrolimus at therapeutic levels unless concurrent AKI with supratherapeutic levels exists.
Bottom Line for Clinical Practice
The default position is to continue tacrolimus with dose adjustment based on levels, not empiric withdrawal. The reversible nature of tacrolimus-induced AKI 2, 3 contrasts sharply with the irreversible consequences of acute rejection from inadequate immunosuppression. Measure levels, adjust doses, investigate alternative causes, and consider biopsy—but do not reflexively stop tacrolimus in AKI without evidence of toxicity.